These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10541377)

  • 1. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
    Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
    Lindén O; Tennvall J; Hindorf C; Cavallin-Ståhl E; Lindner KJ; Ohlsson T; Wingårdh K; Strand SE
    Acta Oncol; 2002; 41(3):297-303. PubMed ID: 12195750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
    Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
    Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
    N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
    Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
    J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
    Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
    Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
    N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD22 as a target of passive immunotherapy.
    Cesano A; Gayko U
    Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
    Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.